Thank You to Our Organizers

SITC President
Mario Sznol, MD – Yale School of Medicine

34th Annual Meeting Organizers
Ana Carrizosa Anderson, PhD – Harvard Medical School

Marawan El-Khatib, MD, PhD – University of Washington

Yeast Cell Biology Organizers
Roman Marrone, MD, PhD – University of Wisconsin

Calvin B. Blalock, MD – Vanderbilt University Medical Center

Marcelo Portillo, MD, PhD – UC San Diego

Michael Davis, PhD – The Anayon Foundation for Immunology

Frank G. Rottenrott, PhD – Malampaya University

Robert Fields, MD, PhD – Lurie Children’s Hospital

Robert M. Zetter, PhD – University of Chicago, Pritzker School of Medicine

Douglas Lock, PhD – Massachusetts Institute of Technology

Jürgen A. Dehler, PhD – University Hospital of the University of Wuerzburg

Helene Oikarinen, MD, PhD – University of California, San Francisco

Virginia Mason, MD – Weill Cornell Medicine

David Reardon, MD, PhD – University of California, Berkeley

David Reardon, MD, PhD – David Reardon Cancer Institute

Katherine Netzlaff, MD, PhD – The University of Texas MD Anderson Cancer Center

Orit Buzin-Raamat, PhD – Ben-Gurion University of the Negev

Kurt A. Schalper, MD, PhD – Yale School of Medicine

Elad Sharon, MD, MPH – National Cancer Institute

Stefani Spranger, PhD – Koch Institute for Integrative Cancer Research at MIT

Ingunn Stromnes, PhD – University of Minnesota

Weijing Sun, MD, FACP – University of Kansas Medical Center

Ahmad A. Tarhini, MD, PhD – Emory University and Winship Comprehensive Cancer Center

John M. Timmerman, MD – University of California, Los Angeles

Jedd D. Wolchok, MD, PhD – Memorial Sloan Kettering Cancer Center

Kwok-Kin Wong, MD, PhD – New York Langone Health

Thank You to Our Session Co-Chairs

Rafi Ahmed, PhD – Emory University

Ana Carrizosa Anderson, PhD – Harvard Medical School

Paolo Antonio Ascierto, MD – Istituto Nazionale Tumori IRCCS Fondazione ‘G. Pascale’

Pierrick Braud, MD, PhD – The Tisch Cancer Institute at The Icahn School of Medicine at Mount Sinai

Shi-Woon Choi, MD – University of Washington

Fabiola Brandao, MD – Princess Margaret Hospital Medical Center

Marianne Davies, DNP, AOCNP – Yale School of Nursing

Michael Davis, PhD – The Anayon Foundation for Immunology

Frank G. Rottenrott, PhD – Malampaya University

Robert Fields, MD, PhD – Lurie Children’s Hospital

Robert M. Zetter, PhD – University of Chicago, Pritzker School of Medicine

Douglas Lock, PhD – Massachusetts Institute of Technology

Jürgen A. Dehler, PhD – University Hospital of the University of Wuerzburg

Helene Oikarinen, MD, PhD – University of California, San Francisco

Virginia Mason, MD – Weill Cornell Medicine

David Reardon, MD, PhD – University of California, Berkeley

David Reardon, MD, PhD – David Reardon Cancer Institute

Katherine Netzlaff, MD, PhD – The University of Texas MD Anderson Cancer Center

Orit Buzin-Raamat, PhD – Ben-Gurion University of the Negev

Kurt A. Schalper, MD, PhD – Yale School of Medicine

Elad Sharon, MD, MPH – National Cancer Institute

Stefani Spranger, PhD – Koch Institute for Integrative Cancer Research at MIT

Ingunn Stromnes, PhD – University of Minnesota

Weijing Sun, MD, FACP – University of Kansas Medical Center

Ahmad A. Tarhini, MD, PhD – Emory University and Winship Comprehensive Cancer Center

John M. Timmerman, MD – University of California, Los Angeles

Jedd D. Wolchok, MD, PhD – Memorial Sloan Kettering Cancer Center

Kwok-Kin Wong, MD, PhD – New York Langone Health

SITC-0519-477

SITC 2019
Gyrald National Hotel & Convention Center
Nov. 6-10
National Harbor, Maryland

Join Us!
SITC 2019: The Premier Gathering Place for the Cancer Immunotherapy Field

With each passing year, the cancer immunotherapy field evolves to produce more ground-breaking research and effective treatment options for patients fighting a host of devastating diseases. Thanks to the advances the field has produced, these patients, and the patients of tomorrow, have a brighter future. But these advances don’t occur in a vacuum or happen accidentally. They require collaboration, funding, learning, discussion and a place where the sharpest minds and most dedicated individuals of the cancer immunotherapy field can gather. That is exactly what the Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting & Pre-Conference Programs (SITC 2019) provide.

As the world’s largest conference solely focused on cancer immunotherapy, SITC 2019 hosts researchers, clinicians, regulators and members of industry from every corner of the globe as they come together to work towards the common goal of improving cancer patient outcomes.

What’s New at SITC 2019

Every year, our goal is to make our Annual Meeting as impactful as possible. SITC 2019 is no exception. Here are some of the highlights:

• Additional Poster Symposium held Thursday night
• The new Career Connections program will connect candidates with employers
• More oral presentation spots than ever before

In this workshop, the current status of intratumoral immunomodulation will be presented and future directions for the field will be discussed, along with their implications for current and forthcoming immunotherapies.

Workshop on Intratumoral Immunomodulation: 8 a.m. – 5 p.m.
Pre-Conference Programs

SITC 2019 • Nov. 6–10, 2019
Gaylord National Hotel & Convention Center, National Harbor, Md.

www.sitcancer.org/2019

For more information on SITC’s Annual Meeting, please visit sitcancer.org/2019

For more information on SITC’s Pre-Conference Programs, please visit sitcancer.org/2019

Pre-Conference Programs Wednesday, Nov. 6, 2019
World Immunotherapy Council’s 3rd Young Investigator Symposium: 8 a.m. – 2 p.m.
SITC and the World Immunotherapy Council (WIC) are dedicated to advancing cancer immunotherapy and the future leaders of the field. This program will provide the opportunity for young scientists and future world leaders to interact, fulfill WIC’s mission to fund state-of-art development and global dissemination of cancer immunotherapies through scientific exchange. This program is supported, in part, by a grant from Bristol-Myers Squibb (as of June 26, 2019)
Novel Multi-Targeted Therapeutic Platforms: 2 – 6:30 p.m.
This program will address the critical scientific, manufacturing and clinical questions that arise in clinical oncology, as well as multi-targeted antibody and related platforms, such as cytokine fusions and cancer vaccines, increasingly make their way into the clinic. Discussions will focus on current and future development trends. This program is open to all meeting attendees. Those interested in applying for the opportunity to present during this program, please contact the SITC Annual Meeting office.
Thursday, Nov. 7, 2019
Primer on Tumor Immunology and Cancer Immunotherapy™: 8 a.m. – 5 p.m.
The Primer on Tumor Immunology and Cancer Immunotherapy™ is a free educational development project for healthcare professionals who wish to learn about the influence of the immune system on cancer development, progression, and treatment outcomes. This Primer is supported, in part, by a grant from Bristol-Myers Squibb and Pfizer, Inc. (as of June 26, 2019)
Workshop on Intratumoral Immunomodulation: 8 a.m. – 5 p.m.
In this workshop, the current status of intratumoral immunomodulation will be presented and future directions for the field will be discussed, along with their implications for current and forthcoming immunotherapies. This program is supported, in part, by a grant from Pfizer, Inc. (as of June 26, 2019)

Grant Writing Workshop: The section title back to black: A look inside the grant review process: 8 – 4 p.m.
This program offers insight into the grant submission process, outlines how to navigate funding opportunities, addresses government and private sector grant submissions, details how to receive an invitation to resubmit, and offers a "meta-study" rationale, allowing attendees to experience a study’s grant proposal evaluation.

Annual Meeting Thursday, Nov. 7 – Sunday, Nov. 10, 2019
The Annual Meeting features cutting-edge research presentations by experts in the field, both oral and poster abstract presentations, and ample opportunity for structured and informal discussions, including important networking opportunities. In addition, the meeting highlights updates on major societal and international initiatives coming from academia, government and industry, as well as important society projects.
The SITC Annual Meeting brings together over 5,000 attendees representing more than 35 countries, disease states and specialties coming together to advance the field of cancer immunotherapy.
Thank You to Our Annual Program Committee

Panel Program Committee Chair
Sandra Demaria, MD
Univ. of Texas MD Anderson Cancer Center

World Immunotherapy Council’s 3rd Young Investigator Symposium Members
David Bedognetti, MD, PhD
Sidra Medicine
Patrick Hwu, MD
The University of Texas MD Anderson Cancer Center
Krista M. Rubin, MS, FNP-BC
University of Pittsburgh

This program is supported, in part, by grants from Bristol-Myers Squibb and Pfizer, Inc. (as of June 26, 2019)

For more information on SITC’s Annual Meeting, please visit sitcancer.org/2019

Abstracts

Submit your latest research in the cancer immunotherapy field to SITC 2019 for consideration as an oral abstract, poster presentation, rapid oral presentation, and/or poster presentation, and/or poster presentation.

Reasons to Submit an Abstract to SITC 2019

• Submissions are free for members and nonmembers alike
• SITC offers Young Investigator Awards in conjunction with SITC 2019
• We publish all accepted abstracts as a supplement in the Journal for ImmunoTherapy of Cancer™, a peer-reviewed journal for the immunotherapy field

Important Abstract Dates

Aug. 3, 2019  Regular Abstracts, Young Investigator Award Abstracts, Late Breaking Abstract Submissions
Aug. 23, 2019  Late-Breaking Abstract Submission Site Open
Aug. 30, 2019  Regular Abstract and Young Investigator award Abstract Submission Sent
Sept. 12, 2019  Late-Breaking Abstract Submission Site Closes at 8 p.m. EDT
Sept. 20, 2019  Late-Breaking Abstract Notification Sent
Nov. 5, 2019  Regular Abstract Supplement Published in JITC
Dec. 5, 2019  Late-Breaking Abstract Supplement Published in JITC

For more information on abstract submission at SITC 2019, please visit sitcancer.org/2019

*Abstracts must be submitted by Aug. 3 at 5 p.m. EDT; for oral or poster presentation eligibility the abstract must be submitted by Aug. 1 at 5 p.m. EDT.

The SITC Annual Meeting and Primer on Tumor Immunology and Cancer Immunotherapy™ are approved for AMA PRA Category 1 Credit™, ANCC contact hours, and ACPM continuing education units. Attendees may also earn MOC points. For CE and MOC information and eligibility, visit ACCESS2019.org.

SITC 2019, please visit sitcancer.org/2019

For more information on abstract submission at SITC 2019, please visit sitcancer.org/2019